BioHarvest Sciences's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-1.72 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.34 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
BioHarvest Sciences's annualizedROC % for the quarter that ended in Mar. 2026 was -34.55%.
BioHarvest Sciences's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -39.17%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
BioHarvest Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -14.71%.
BioHarvest Sciences (NAS:BHST) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
BioHarvest Sciences's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, BioHarvest Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (BHST) has a EBIT of $-8.34 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioHarvest Sciences.
Is BioHarvest Sciences' EBIT too high?
BioHarvest Sciences' current EBIT is $-8.34 Mil. Overall, BioHarvest Sciences has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' EBIT compare to GWLL and CLNN?
BioHarvest Sciences' EBIT of $-8.34 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioHarvest Sciences. BioHarvest Sciences's current EBIT is $-8.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.57, compared to a current price of $2.77 — trading 67.7% below its estimated fair value. The current EBIT is $-8.34 Mil. BioHarvest Sciences' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current EBIT is $-8.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $2.77 is trading 67.7% below its estimated GF Value™ of $8.57.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
EBIT: $-8.34 Mil
GF Value™: $8.57 vs. price of $2.77 (67.7% below fair value)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
64GF Score
Get the complete analysis for BHST
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
